Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma

@article{Ohtsu2000PhaseIS,
  title={Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma},
  author={Atsushi Ohtsu and Hironori Baba and Yuh Sakata and Yasushi Mitachi and Noboru Horikoshi and Keishi Sugimachi and Tetsuo Taguchi},
  journal={British Journal of Cancer},
  year={2000},
  volume={83},
  pages={141 - 145}
}
This study set out to evaluate, in patients with metastatic colorectal carcinoma, the efficacy and toxicity of S-1, which contains tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate, based on a biochemical modulation of 5-fluorouracil (5-FU) targeted at inhibition of dihydropyrimidine dehydrogenase (DPD). Sixty-three patients with measurable metastatic colorectal carcinoma were enrolled into the study. None of the patients had received prior chemotherapy except for adjuvant… CONTINUE READING